


ASCO 2024 Key Highlights




Key Findings

This summary examines the clinical trial environment for industry-sponsored trials with data showcased at ASCO 2024 to identify the types of products being developed, types of cancer being studied, at what stage of development, in which regions, and for which group of patients.


A significant number of innovative therapies are being researched; the immuno-oncology mechanism of action remains at the forefront of drug development, with PD-1/L1 inhibitors the top choice in this field. Most of the trials featured at ASCO 2024 focused on immuno-oncology drugs.

Trials by Primary Tested Drug Mechanisms of Action



Trials by Sponsor


Around 46% of the industry-sponsored trials presented at ASCO 2024 were conducted by **Top 20*** pharma companies. Merck & Co. dominated the space, followed by AstraZeneca, Bristol Myers Squibb, and Roche.




*"Top 20 pharma" defined per Scrip 100 ranking of drug sales, 2022

Trial Counts per Cancer Type and Phase

Non-small cell lung cancer is the most researched cancer type, followed by breast and colorectal cancers. Furthermore, most of the industry-sponsored trials presented at ASCO 2024 were in Phase II with 46% phase II trials having completed trial status.



Trials by Phase




Geographic Distribution

The US holds the leading position as the location where most trials are conducted, followed by China and Spain. Over 64% of industry-sponsored trials presented at ASCO 2024 had a trial location in the US.



Trials Based on Patient Population

Many trials focused on enrolling patients based on genetic mutations or alterations. A significant portion of these trials were either first in human or pivotal clinical trials aimed at gaining initial market approval through regulatory submission.



Citeline customers can access the full ASCO 2024 Datapack here:

ASCO 2024

For information on how you can obtain exclusive reports like this one, contact us at:

clientservices@citeline.com

